Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer

Dmitri Pchejetski (Lead Author), Albandri Alfraidi, Keith Sacco, Heba Alshaker, Aun Muhammad, Leonardo Monzon

Research output: Contribution to journalLiterature reviewpeer-review

22 Citations (Scopus)
10 Downloads (Pure)


Introduction: In developed countries, ovarian cancer is the fourth most common cancer in women. Due to the nonspecific symptomatology associated with the disease many patients with ovarian cancer are diagnosed late, which leads to significantly poorer prognosis. Apart from surgery and radiotherapy, a substantial number of ovarian cancer patients will undergo chemotherapy and platinum based agents are the mainstream first-line therapy for this disease. Despite the initial efficacy of these therapies, many women relapse; therefore, strategies for second-line therapies are required. Regulation of DNA transcription is crucial for tumour progression, metastasis and chemoresistance which offers potential for novel drug targets.

Methods: We have reviewed the existing literature on the role of histone deacetylases, nuclear enzymes regulating gene transcription.

Results and conclusion: Analysis of available data suggests that a signifant proportion of drug resistance stems from abberant gene expression, therefore HDAC inhibitors are amongst the most promising therapeutic targets for cancer treatment. Together with genetic testing, they may have a potential to serve as base for patient-adapted therapies.
Original languageEnglish
Pages (from-to)1659–1671
Number of pages13
JournalJournal of Cancer Research and Clinical Oncology
Issue number8
Early online date11 Nov 2015
Publication statusPublished - Aug 2016


  • Platinum resistance
  • Ovarian cancer
  • Platinum
  • Chemotherapy
  • Molecular targeting

Cite this